HALLE/SAALE, Germany, October 8, 2013 – Probiodrug AG (Probiodrug) today announced that Dr Konrad Glund, the Company’s chief executive officer, will be providing an update of corporate and clinical accomplishments at the 12th Annual BIO Investor Forum on Wednesday, October 9, 2013, at 2:30 p.m. PDT. The conference is taking place at the Palace Hotel in San Francisco, CA.
Probiodrug is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions to treat people with Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase, providing the Company with a dominant position in this field of research. Probiodrug is backed by institutions such as Edmond de Rothschild Investment Partners, BB Biotech, IBG, HBM, TVM Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group, funds managed by Wellington Management and private investors.
Probiodrug’s core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. Probiodrug was founded in 1997 by Prof Dr Hans-Ulrich Demuth and Dr Konrad Glund. For more information, please visit www.probiodrug.de.
Dr. Konrad Glund, CEO
Tel: +49 (345) 555-9900